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1. INTRODUCTION {#jcmm15097-sec-0001}
===============

Nasopharyngeal carcinoma (NPC) is a malignant epithelial cancer that occurs in the epithelial lining of the nasopharynx with the highest rate of metastasis among head and neck cancers.[1](#jcmm15097-bib-0001){ref-type="ref"} NPC has an extraordinarily skewed geographic distribution worldwide, which is mainly prevalent in southern China and South‐East Asian countries.[1](#jcmm15097-bib-0001){ref-type="ref"} More than 129 000 new cases of NPC were reported worldwide, and the incidence of the male is higher than that of female.[1](#jcmm15097-bib-0001){ref-type="ref"} The mortality from cancer is mostly attributable to metastases, not the primary cancers, and the effective treatment for cancer depends mainly on our capacity to reverse the process of metastasis.[2](#jcmm15097-bib-0002){ref-type="ref"} Intensity‐modulated radiation therapy (IMRT) and concurrent chemotherapy are regarded as the primary treatment for NPC.[3](#jcmm15097-bib-0003){ref-type="ref"} However, the treatment is related to acute and late toxicities with impairment of patients' quality of life,[4](#jcmm15097-bib-0004){ref-type="ref"} such as dysphagia.[5](#jcmm15097-bib-0005){ref-type="ref"}, [6](#jcmm15097-bib-0006){ref-type="ref"} Other side effects, such as the arrest of bone marrow, radiation stomatitis and dermatitis, need to be further investigated.

The classification method of NPC is mainly relied on the tumour‐node‐metastasis (TNM) staging criteria, which is used for treatment selection, cancer control activities and outcome prediction. However, the failure to consider the functional status of NPC leads to different prognoses in patients with the same TNM staging.[7](#jcmm15097-bib-0007){ref-type="ref"} More reliable markers are necessary to supply clinical diagnosis and treatment.

The inflammatory responses play an essential role in various stages of cancer development, including occurrence, progression, malignant conversion, invasion and metastasis, and moreover, the inflammation affects immune surveillance and responses to therapy.[8](#jcmm15097-bib-0008){ref-type="ref"} Solid malignancies trigger an intrinsic inflammatory response and then building up a pro‐tumorigenic microenvironment, which promotes the development of cancers.[9](#jcmm15097-bib-0009){ref-type="ref"} Cancers contain various noncancerous cells including immune cells, such as T cells, macrophages and neutrophils. These cells can be anti‐ or tumorigenic and associate with survival in several cancer types.[10](#jcmm15097-bib-0010){ref-type="ref"}

The inflammation indicators including neutrophils,[11](#jcmm15097-bib-0011){ref-type="ref"} lymphocytes and monocytes,[12](#jcmm15097-bib-0012){ref-type="ref"} and red cell volume distribution width (RDW)[13](#jcmm15097-bib-0013){ref-type="ref"} have prognostic value in cancers. The integration of two types of white blood cell indicators, such as the neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR) and lymphocyte‐monocyte ratio (LMR), is considered to be independent prognostic factors for colorectal cancer.[14](#jcmm15097-bib-0014){ref-type="ref"} Recently, immune‐inflammation indexes including the systemic inflammatory response index (SIRI) based on three types of white cells (peripheral neutrophils, monocytes and lymphocytes) and the systemic immune‐inflammation index (SII) based on three types of white cells (peripheral neutrophils, platelet and lymphocytes) were investigated in various cancers.[15](#jcmm15097-bib-0015){ref-type="ref"}, [16](#jcmm15097-bib-0016){ref-type="ref"} These inflammation indexes are also considered to be independent prognostic factors for cancers, and their prognostic value is higher than that of only white blood cells. However, the cut‐off value of immune‐inflammation indicators is diverse in different cancers. The cut‐off value of SII, NLR and PLR in non--small‐cell lung cancer is 660, 3.57 and 147, respectively,[16](#jcmm15097-bib-0016){ref-type="ref"} while these values in metastatic prostate cancer are 535, 3 and 210, respectively.[17](#jcmm15097-bib-0017){ref-type="ref"} There are few reports on the relationship between combined inflammation indicators and NPC prognosis, and the basophil has never been reported in NPC prognosis.

In this study, we investigated the efficiency of these inflammation indicators on the diagnosis of NPC, and these inflammation indicators can be established as a mechanism for predicting prognosis of cancer patients in clinical settings that would help for future novel treatments.

2. MATERIALS AND METHODS {#jcmm15097-sec-0002}
========================

2.1. Patients {#jcmm15097-sec-0003}
-------------

We retrospectively recruited 559 patients who were diagnosed as NPC at the Zhongnan Hospital of Wuhan University from January 2014 to November 2018. NPC patients were comprised by 421 males and 138 females with a median age of 51 (range 12‐83 years). To verify the predictive value of the immune‐inflammation indicators for diagnosis of NPC, we retrospectively recruited other 500 patients diagnosed as rhinitis in the same period as normal group who were comprised by 312 males and 188 females with a median age of 46 (range 10‐83 years). The seventh edition of the American Joint Committee on Cancer (AJCC) staging system was used for stage classification. This study was carried out in accordance with the recommendations of Zhongnan Hospital of Wuhan University Ethics and Scientific Committee with written informed consent from all patients. All patients gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Zhongnan Hospital of Wuhan University Ethics and Scientific Committee.

2.2. Inclusion and exclusion criteria {#jcmm15097-sec-0004}
-------------------------------------

The inclusion criteria in this study comprised of: (a) patients with histopathological confirmation of NPC; (b) patients with proper renal, cardiac and liver function to tolerate chemotherapy and radiotherapy; and (c) patients with a complete record of haematological indicators. Exclusion criteria were as follows: (a) patients with other types of malignancy. Finally, we have retrieved data of 255 patients with complete follow‐up data using for survival analysis.

2.3. Haematological examination {#jcmm15097-sec-0005}
-------------------------------

Fasting whole blood from every patient was collected in an EDTA anticoagulant‐treated tube on the admission without the next step of treatment, and analysed within 30 minutes of collection. Routine peripheral blood cells, including total white cell count (WBC), red blood cell count (RBC), platelet count (PLT), differential white cell count (neutrophils, lymphocytes, monocytes, eosinophils and basophils), haemoglobin (HGB), haematocrit (HCT), mean cell volume (MCV), mean cell haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), red cell distribution width (RDW) and mean platelet volume (MPV), were analysed by Beckman Coulter DxH 800 automated blood analyser and related reagents (Beckman, California, USA). The combination of two or three haematological inflammation parameters, SIRI, SII, NLR and PLR, is defined as follows: SIRI = neutrophils × monocytes/lymphocytes;NLR = neutrophils/lymphocytes;SII = neutrophils × platelets/lymphocytes;PLR = platelets/lymphocytes;

ROC curves determined the optimal cut‐off values for prognostic inflammation indicators (area under the curve \> 50%).[18](#jcmm15097-bib-0018){ref-type="ref"} The optimal cut‐off values were as follows: SIRI (1.529), NLR (3.441), SII (715.739), PLR (245.496), neutrophil (2.722), monocyte (0.578), platelet (267.583), WBC (6.177), basophil (0.029) and RDW (14.495).

2.4. Follow‐up {#jcmm15097-sec-0006}
--------------

We chose the OS and DFS as the primary end‐point and secondary end‐point, respectively. Patients diagnosed as NPC were followed up primarily by telephone and periodic review in hospital. A total of 255 of 559 patients were followed up successfully. OS was defined as the period from the initial diagnosis to death regardless of NPC related or not or the last follow‐up. The median follow‐up time among the 255 patients was 33.5 months, ranging from 2.1 months to 151.2 months. DFS was defined as the period from the initial diagnosis to recurrence or metastasis. Follow‐ups were ended in February 2019.

2.5. Statistical analysis {#jcmm15097-sec-0007}
-------------------------

Statistical analyses were conducted using IBM SPSS version 22.0 software (SPSS, Chicago, IL). Continuous variables and qualitative variables were measured by t test and chi‐square test and plotted by GraphPad Prism V7.0 software. The correlations between clinical factors and SIRI, SII, NLR, neutrophil and monocyte were analysed by chi‐square test. The Kaplan‐Meier methods and the log‐rank test were used to estimate OS and DFS. The independent prognostic risk factors for survival were analysed by univariate and multivariate Cox proportional hazards regression model. The logistic regression analysis was used to analyse the influencing factors of side effects after treatment. Receiver operating characteristic (ROC) curve was applied to determine optimal cut‐off values and assess the predictive ability of prognostic indicators.[19](#jcmm15097-bib-0019){ref-type="ref"} A *P*‐value \< .05 was considered statistically significant.

3. RESULTS {#jcmm15097-sec-0008}
==========

3.1. Baseline characteristics of NPC and rhinitis patients {#jcmm15097-sec-0009}
----------------------------------------------------------

NPC and rhinitis were both common in men and younger patients (Table [1](#jcmm15097-tbl-0001){ref-type="table"}). Clinical parameters between NPC patients and rhinitis patients are shown in Figure [1](#jcmm15097-fig-0001){ref-type="fig"}. Most immune‐inflammation indicators between two cohorts, such as PLR, NLR, SIRI and SII, were significantly different. To investigate the diagnostic significance of immunological indexes in NPC patients, ROC curve analysis was performed. As shown in Figure [2](#jcmm15097-fig-0002){ref-type="fig"}, the AUC values for PLR, NLR, NEU, SIRI, SII and MONO were 0.699, 0.659, 0.640, 0.638, 0.637 and 0.622, while the AUC value for RDW was 0.578. These data suggested that PLR NLR, SIRI, SII, NEU and MONO could distinguish NPC from rhinitis.

###### 

General characteristics of NPC and rhinitis cohort

  Variables          All patients   NPC with follow‐up   
  ------------------ -------------- -------------------- -------------
  Sex                                                    
  Male               421 (75.3%)    312 (62.4%)          202 (79.2%)
  Female             138 (24.7%)    188 (37.6)           53 (20.8%)
  Age                                                    
  \<60               422 (75.5%)    410 (82.0%)          193 (75.7%)
  ≥60                137 (24.5%)    90 (18.0%)           62 (24.3%)
  T                                                      
  T1                 65 (11.6%)     n.a.                 33 (12.9%)
  T2                 166 (29.7%)    n.a.                 70 (27.5%)
  T3                 162 (29%)      n.a.                 70 (27.5%)
  T4                 166 (29.7%)    n.a.                 82 (32.1%)
  N                                                      
  N0                 43 (7.7%)      n.a.                 18 (7.1%)
  N1                 91 (16.3%)     n.a.                 43 (16.8%)
  N2                 338 (60.5%)    n.a.                 156 (61.2%)
  N3                 87 (15.5%)     n.a.                 38 (14.9%)
  M                                                      
  M0                 492 (88%)      n.a.                 231 (90.6%)
  M1                 67 (12%)       n.a.                 24 (9.4%)
  Histology (WHO)                                        
  Keratinizing       12 (2.1%)      n.a.                 6 (2.4%)
  Non‐keratinizing   527 (94.3%)    n.a.                 243 (95.2%)
  Unknown            20 (3.6%)      n.a.                 6 (2.4%)

Abbreviations: TNM, tumour node metastasis; n.a, not applicable; WHO, World Health Organization.

Keratinizing squamous cell carcinoma; Non‐keratinizing carcinoma.
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![General characteristics of haematological parameters between NPC and rhinitis patients. A, WBC (left), RBC (middle) and HGB (right). B, NEU% (left), LYM% (middle) and MONO% (right). C, EO% (left), LYM (middle) and PLR (right). D, NLR (left), MONO (middle) and LMR (right). E, SIRI (left), SII (middle) and EO (right). F, HCT (left), RDW (middle) and MPV (right)](JCMM-24-8326-g001){#jcmm15097-fig-0001}

![The diagnostic significance of immunological indexes was analysed via establishing ROC curve in NPC. The curve demonstrated that immunological indexes could discriminate NPC from rhinitis](JCMM-24-8326-g002){#jcmm15097-fig-0002}

3.2. The association between clinical indexes and haematological indicators in NPC patients {#jcmm15097-sec-0010}
-------------------------------------------------------------------------------------------

The association between haematological indicators and clinical characteristics in 559 NPC patients was shown in Table [2](#jcmm15097-tbl-0002){ref-type="table"}, and haematological indicators in a different circumstance, including therapy, TNM staging system and histopathological classification, were displayed in Figures [3](#jcmm15097-fig-0003){ref-type="fig"}, [4](#jcmm15097-fig-0004){ref-type="fig"}, [5](#jcmm15097-fig-0005){ref-type="fig"}, [6](#jcmm15097-fig-0006){ref-type="fig"}. Significant differences in the haematological indicators were diverse in sex, age and metastasis status (Table [2](#jcmm15097-tbl-0002){ref-type="table"}). Moreover, common differences in inflammation indicators (such as SII and PLR) in multiple comparative analysis can be observed (Figures [4](#jcmm15097-fig-0004){ref-type="fig"}, [5](#jcmm15097-fig-0005){ref-type="fig"}). However, there were not significant differences in inflammation indicators in therapy and histopathological groups despite the difference in platelets in these groups (Figures [3](#jcmm15097-fig-0003){ref-type="fig"} and [6](#jcmm15097-fig-0006){ref-type="fig"}).

###### 

General characteristics of haematological parameters of 559 included patients

  Parameters   Sex                 $\overline{x} \pm s$   *P*                 Age    $\overline{x} \pm s$   *P*     M    $\overline{x} \pm s$   *P*
  ------------ ------------------- ---------------------- ------------------- ------ ---------------------- ------- ---- ---------------------- -------
  WBC          M                   6.156 ± 2.313          .000                \<60   5.958 ± 2.249          0.828   M0   5.923 ± 2.295          .570
  F            5.307 ± 1.898       ≥60                    5.910 ± 2.245       M1     6.116 ± 2.600                                              
  RBC          M                   4.433 ± 0.557          .000                \<60   4.385 ± 0.579          .000    M0   4.363 ± 0.559          0.002
  F            4.040 ± 0.471       ≥60                    4.187 ± 0.480       M1     4.139 ± 0.554                                              
  HGB          M                   134.065 ± 15.321       .000                \<60   131.281 ± 16.645       0.116   M0   131.745 ± 15.585       .000
  F            120.291 ± 14.562    ≥60                    128.766 ± 14.867    M1     122.736 ± 18.793                                           
  PLT          M                   211.572 ± 72.830       0.264               \<60   219.929 ± 73.449       .000    M0   210.878 ± 70.164       0.051
  F            219.565 ± 72.707    ≥60                    193.883 ± 67.371    M1     233.134 ± 88.097                                           
  NEU%         M                   63.033 ± 9.828         0.096               \<60   62.516 ± 10.038        0.621   M0   62.098 ± 9.743         0.001
  F            61.415 ± 10.132     ≥60                    62.999 ± 9.572      M1     66.570 ± 10.383                                            
  LYM%         M                   25.502 ± 8.647         0.016               \<60   26.342 ± 8.670         0.114   M0   26.632 ± 8.569         .000
  F            27.561 ± 8.703      ≥60                    24.989 ± 8.737      M1     21.443 ± 8.324                                             
  MONO%        M                   8.713 ± 2.900          0.139               \<60   8.441 ± 3.539          0.063   M0   8.538 ± 3.425          0.309
  F            8.222 ± 4.541       ≥60                    9.058 ± 2.804       M1     8.987 ± 3.037                                              
  EO%          M                   2.106 ± 2.169          .750                \<60   2.070 ± 2.408          0.351   M0   2.111 ± 2.311          0.781
  F            2.182 ± 3.081       ≥60                    2.293 ± 2.472       M1     2.222 ± 3.145                                              
  BASO%        M                   0.648 ± 0.746          0.678               \<60   0.633 ± 0.745          0.653   M0   0.623 ± 0.436          .460
  F            0.620 ± 0.453       ≥60                    0.664 ± 0.457       M1     0.769 ± 1.595                                              
  NEUT         M                   3.979 ± 1.973          0.001               \<60   3.822 ± 1.921          0.992   M0   3.770 ± 1.862          0.124
  F            3.344 ± 1.594       ≥60                    3.820 ± 1.863       M1     4.203 ± 2.171                                              
  LYM          M                   1.496 ± 0.596          0.081               \<60   1.496 ± 0.593          0.079   M0   1.504 ± 0.571          .000
  F            1.397 ± 0.528       ≥60                    1.396 ± 0.537       M1     1.234 ± 0.605                                              
  PLR          M                   163.952 ± 99.331       0.118               \<60   170.324 ± 95.494       .250    M0   158.390 ± 78.420       .000
  F            178.850 ± 89.078    ≥60                    159.333 ± 101.549   M1     235.486 ± 168.960                                          
  NLR          M                   3.079 ± 2.291          0.051               \<60   2.926 ± 2.144          0.331   M0   2.811 ± 1.775          0.004
  F            2.667 ± 1.644       ≥60                    3.132 ± 2.191       M1     4.197 ± 3.758                                              
  MONO         M                   0.518 ± 0.215          .000                \<60   0.484 ± 0.237          0.106   M0   0.490 ± 0.231          .330
  F            0.418 ± 0.261       ≥60                    0.521 ± 0.209       M1     0.519 ± 0.233                                              
  LMR          M                   3.264 ± 2.171          0.005               \<60   3.510 ± 2.613          0.395   M0   3.483 ± 2.084          0.483
  F            4.029 ± 4.112       ≥60                    3.276 ± 3.295       M1     3.228 ± 5.799                                              
  SIRI         M                   1.687 ± 1.821          0.001               \<60   1.488 ± 1.534          0.119   M0   1.456 ± 1.449          0.016
  F            1.197 ± 1.364       ≥60                    1.807 ± 2.220       M1     2.375 ± 2.992                                              
  SII          M                   676.431 ± 695.005      0.228               \<60   663.442 ± 592.547      0.709   M0   604.570 ± 486.474      0.005
  F            600.356 ± 449.140   ≥60                    639.811 ± 782.321   M1     1047.435 ± 1251.348                                        
  EO           M                   0.124 ± 0.147          0.496               \<60   0.118 ± 0.149          0.262   M0   0.123 ± 0.152          0.773
  F            0.114 ± 0.176       ≥60                    0.135 ± 0.170       M1     0.117 ± 0.174                                              
  BASO         M                   0.037 ± 0.035          0.165               \<60   0.035 ± 0.035          0.694   M0   0.036 ± 0.033          0.934
  F            0.032 ± 0.028       ≥60                    0.037 ± 0.031       M1     0.036 ± 0.042                                              
  HCT          M                   40.298 ± 4.607         .000                \<60   39.485 ± 5.019         0.083   M0   39.572 ± 4.706         .000
  F            36.181 ± 4.302      ≥60                    38.656 ± 4.316      M1     37.155 ± 5.496                                             
  MCV          M                   91.171 ± 5.353         0.006               \<60   90.266 ± 5.557         .000    M0   90.950 ± 5.314         0.094
  F            89.697 ± 5.628      ≥60                    92.474 ± 4.772      M1     89.760 ± 6.340                                             
  MCH          M                   30.353 ± 2.121         0.013               \<60   30.037 ± 2.190         .000    M0   30.302 ± 2.071         0.022
  F            29.833 ± 2.183      ≥60                    30.803 ± 1.898      M1     29.661 ± 2.579                                             
  MCHC         M                   332.794 ± 9.186        .660                \<60   332.592 ± 8.963        0.609   M0   333.052 ± 8.661        0.012
  F            332.425 ± 8.311     ≥60                    333.044 ± 9.024     M1     330.137 ± 10.720                                           
  RDW          M                   13.481 ± 1.115         0.062               \<60   13.520 ± 1.295         0.371   M0   13.465 ± 1.084         0.007
  F            13.748 ± 1.545      ≥60                    13.629 ± 1.048      M1     14.148 ± 1.956                                             
  MPV          M                   8.627 ± 1.199          0.007               \<60   8.711 ± 1.286          0.821   M0   8.747 ± 1.285          0.147
  F            8.996 ± 1.421       ≥60                    8.739 ± 1.208       M1     8.507 ± 1.105                                              

Abbreviations: HGB, haemoglobin; PLT, platelet; NEU, neutrophil; LYM, lymphocyte; MONO, monocyte; EO, eosinophil; BASO, basophil; PLR, platelet‐lymphocyte ratio; NLR, neutrophil‐lymphocyte ratio; LMR, lymphocyte‐monocyte ratio; SIRI, systemic inflammation response index; SII, systemic immune‐inflammation index; HCT, haematocrit; MCV, erythrocyte mean corpuscular volume; MCH, erythrocyte mean corpuscular haemoglobin; MCHC, erythrocyte mean corpuscular haemoglobin concentrate; RDW, erythrocyte haemoglobin distribution width; MPV, mean platelet volume.
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![Effects of therapy on haematological parameters. A, WBC (left), RBC (middle) and HGB (right). B, NEU (left), LYM (middle) and MONO (right). C, PLT (left), PLR (middle) and NLR (right). D, SIRI (left), SII (middle) and RDW (right). E, HCT (left), MPV (middle) and MCH (right). F, EO (left), BASO (middle) and MCHC (right). Radiotherapy included the chemoradiotherapy and radiotherapy alone](JCMM-24-8326-g003){#jcmm15097-fig-0003}

![Effects of T stage on haematological parameter. A, RBC (left), HGB (middle) and PLT (right). B, NEU% (left), LYM% (middle) and MONO% (right). C, EO% (left), NEU (middle) and PLR (right). D, LMR (left), SII (middle) and EO (right). E, HCT (left), MCHC (middle) and MPV (right)](JCMM-24-8326-g004){#jcmm15097-fig-0004}

![Effects of N stage on haematological parameter. A, WBC (left), PLT (middle) and NEU% (right). B, LYM% (left), NEU (middle) and LYM (right). C, PLR (left), NLR (middle) and MONO (right). D, SIRI (left), SII (middle) and EO (right). E, MCV (left), MCH (middle) and MCHC (right)](JCMM-24-8326-g005){#jcmm15097-fig-0005}

![Effects of pathological type on haematological parameters. A, WBC (left), RBC (middle) and HGB (right). B, PLT (left), NEU (middle) and MONO (right). C, LYM (left), BASO (middle) and PLR (right). D, NLR (left), LMR (middle) and SIRI (right). E, SII (left), RDW (middle) and MCV (right)](JCMM-24-8326-g006){#jcmm15097-fig-0006}

3.3. Influence of clinical indexes and haemograms on side effects {#jcmm15097-sec-0011}
-----------------------------------------------------------------

A total of 509 of 559 NPC patients received radiotherapy, but 2 patients of them were deficient in clinical data and therefore excluded in our study. Then, 507 patients were included in the study for side effects (Table [S1](#jcmm15097-sup-0001){ref-type="supplementary-material"}). Common side effects of treatment in our study consisted of the arrest of bone marrow, radiodermatitis, radiation stomatitis, skin pigmentation after radiotherapy, dysphagia, gastrointestinal reaction and innutrition. Part of these patients was confronted with these side effects, including bacterial infection, secondary anaemia, hypoproteinaemia, post‐radiotherapy moult, electrolyte disturbances, secondary thrombocytopenia, abnormal liver function and agranulocytosis. We conducted a study on the factors affecting the side effects of treatment. Results analysed by multivariate logistic regression analysis are shown in Tables [3](#jcmm15097-tbl-0003){ref-type="table"}, [4](#jcmm15097-tbl-0004){ref-type="table"}, [5](#jcmm15097-tbl-0005){ref-type="table"}, [6](#jcmm15097-tbl-0006){ref-type="table"}. The independent risk factors for the arrest of bone marrow included, lymphocyte, eosinophil, HCT and MCV (Table [3](#jcmm15097-tbl-0003){ref-type="table"}). The independent risk factors for the radiodermatitis included lymphocyte and eosinophil (Table [3](#jcmm15097-tbl-0003){ref-type="table"}), and the independent risk factors for the radiation stomatitis included haemoglobin, platelet, lymphocyte, monocyte, eosinophil and basophil (Table [4](#jcmm15097-tbl-0004){ref-type="table"}). And the independent risk factors for the skin pigmentation after radiotherapy included age, PLR, eosinophil and HCT (Table [4](#jcmm15097-tbl-0004){ref-type="table"}). The independent risk factors for the dysphagia included eosinophil, HCT and PLR (Table [5](#jcmm15097-tbl-0005){ref-type="table"}), and the independent risk factors for the gastrointestinal reaction included sex, SIRI, M stage, eosinophil and HCT (Table [5](#jcmm15097-tbl-0005){ref-type="table"}). Haemoglobin, NLR and age were the independent risk factors for the innutrition (Table [6](#jcmm15097-tbl-0006){ref-type="table"}). Age, eosinophil and HCT affected most side effects in the treatment of NPC patients, while T stage, N stage, histology, neutrophil and SII had no impact on these side effects.

###### 

Effects of clinical parameters and hemograms on the arrest of bone marrow and radiodermatitis in NPC patients (n = 507)

  Variables            n     Arrest of bone marrow   Radiodermatitis                                  
  -------------------- ----- ----------------------- ----------------- ------- ------- -------------- ------
  Sex                        1.428                   0.845‐2.412       .183    1.234   0.767‐1.986    .385
  Male                 386   Ref.                                              Ref.                   
  Female               121                                                                            
  Age                        1.289                   0.777‐2.138       .325    0.669   0.433‐1.034    .070
  \<60                 389   Ref.                                              Ref.                   
  ≥60                  118                                                                            
  T                                                                    .387                           .735
  T1                   62    Ref.                                              Ref.                   
  T2                   149   0.828                   0.400‐1.720       .613    1.220   0.629‐2.366    .556
  T3                   151   1.227                   0.590‐2.549       .584    1.218   0.619‐2.395    .568
  T4                   145   0.785                   0.375‐1.644       .521    0.962   0.489‐1.892    .910
  N                                                                    .100                           .950
  N0                   40    Ref.                                              Ref.                   
  N1                   84    0.434                   0.183‐1.030       .058    0.817   0.357‐1.866    .631
  N2                   305   0.494                   0.231‐1.059       .070    0.915   0.436‐1.923    .815
  N3                   78    0.317                   0.126‐0.797       .015    0.834   0.351‐1.984    .681
  M                          1.277                   0.670‐2.432       .457    1.635   0.927‐2.885    .090
  M0                   436   Ref.                                              Ref.                   
  M1                   71                                                                             
  Histology                                                            .142                           .495
  Keratinizing\*       12    Ref.                                              Ref.                   
  Non‐Keratinizing\#   479   0.361                   0.099‐1.319       .123    0.414   0.097‐1.777    .235
  Unknown              16    0.763                   0.141‐4.111       .753    0.417   0.070‐2.492    .337
  SIRI                       1.219                   0.615‐2.414       .571    0.852   0.452‐1.606    .621
  \<1.529              367   Ref.                                              Ref.                   
  ≥1.529               140                                                                            
  NLR                        0.922                   0.411‐2.068       .844    1.179   0.553‐2.511    .670
  \<3.441              377   Ref.                                              Ref.                   
  ≥3.441               130                                                                            
  SII                        0.935                   0.432‐2.025       .865    1.069   0.505‐2.263    .861
  \<715.739            384   Ref.                                              Ref.                   
  ≥715.739             123                                                                            
  PLR                        1.776                   0.903‐3.492       .096    1.158   0.518‐2.589    .720
  \<245.496            442   Ref.                                              Ref.                   
  ≥245.496             65                                                                             
  WBC                                                                  .049                           .850
  Normal               341   Ref.                                              Ref.                   
  Low                  146   0.531                   0.319‐0.885       .015    1.229   0.593‐2.548    .579
  High                 20    1.038                   0.366‐2.945       .944    0.853   0.132‐5.489    .867
  RBC                                                                  .390                           .335
  Normal               324   Ref.                                              Ref.                   
  Low                  178   1.223                   0.621‐2.408       .560    1.510   0.832‐2.740    .176
  High                 5     5.164                   0.399‐66.905      .209    0.464   0.044‐4.942    .525
  HGB                        0.618                   0.319‐1.198       .154    0.687   0.382‐1.236    .210
  Normal               330   Ref.                                              Ref.                   
  Low                  177                                                                            
  PLT                                                                  .476                           .370
  Normal               455   Ref.                                              Ref.                   
  Low                  15    1.008                   0.225‐4.520       .992    1.501   0.420‐5.362    .532
  High                 37    1.690                   0.727‐3.932       .223    1.787   0.735‐4.346    .200
  NEU                                                                  .591                           .268
  Normal               370   Ref.                                              Ref.                   
  Low                  109   0.834                   0.380‐1.832       .652    0.557   0.270‐1.148    .112
  High                 28    0.468                   0.091‐2.414       .364    0.769   0.145‐4.089    .758
  LYM                                                                  .001                           .022
  Normal               379   Ref.                                              Ref.                   
  Low                  127   2.939                   1.655‐5.218       .000    1.878   1.202‐2.936    .006
  High                 1     7.951E+09               0‐                .999    0.000   0‐             .999
  MONO                       1.561                   0.682‐3.577       0.292   1.063   0.502‐2.248    .873
  Normal               463   Ref.                                              Ref.                   
  High                 44                                                                             
  EO                                                                   .000                           .002
  Normal               210   Ref.                                              Ref.                   
  Low                  290   0.343                   0.227‐0.519       .000    0.502   0.342‐0.736    .000
  High                 7     0.297                   0.049‐1.787       .185    1.122   0.206‐6.107    .894
  BASO                       0.646                   0.156‐2.668       .546    0.252   0.062‐1.021    .053
  Normal               497   Ref.                                              Ref.                   
  High                 10                                                                             
  HCT                        0.489                   0.317‐0.754       .001    0.861   0.524‐1.412    .553
  Normal               154   Ref.                                              Ref.                   
  Low                  353                                                                            
  MCV                                                                  .002                           .954
  Normal               483   Ref.                                              Ref.                   
  Low                  13    6.694                   2.002‐22.377      .002    0.922   0.055‐15.414   .955
  High                 11    3.154                   0.831‐11.974      .091    1.277   0.262‐6.217    .762
  MCH                                                                  .487                           .350
  Normal               485   Ref.                                              Ref.                   
  Low                  12    0.325                   0.020‐5.256       .428    4.112   0.173‐97.498   .381
  High                 10    2.246                   0.390‐12.924      .365    2.934   0.466‐18.493   .252
  MCHC                                                                 .545                           .619
  Normal               481   Ref.                                              Ref.                   
  Low                  23    1.754                   0.565‐5.441       .331    1.744   0.573‐5.309    .327
  High                 3     0.454                   0.024‐8.660       .600    0.971   0.059‐15.998   .984
  RDW                        0.974                   0.475‐1.997       .943    0.849   0.456‐1.581    .606
  Normal               436   Ref.                                              Ref.                   
  High                 71                                                                             
  MPV                        1.190                   0.024‐59.676      .931    0.484   0.018‐12.830   .665
  Normal               505   Ref.                                              Ref.                   
  High                 2                             ‐                                                

Keratinizing squamous cell carcinoma; non‐keratinizing carcinoma.
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###### 

Effects of clinical parameters and hemograms on the radiation stomatitis and skin pigmentation after radiotherapy in NPC patients (n = 507)

  Variables            n     Radiation stomatitis   Skin pigmentation after radiotherapy                                       
  -------------------- ----- ---------------------- -------------------------------------- ------- ----------- --------------- ------
  Sex                        1.211                  0.740‐1.984                            .446    0.942       0.576‐1.540     .811
  Male                 386   Ref.                                                                  Ref.                        
  Female               121                                                                                                     
  Age                        0.656                  0.416‐1.036                            .070    1.656       1.027‐2.671     .039
  \<60                 389   Ref.                                                                  Ref.                        
  ≥60                  118                                                                                                     
  T                                                                                        .258                                .348
  T1                   62    Ref.                                                                  Ref.                        
  T2                   149   1.666                  0.845‐3.285                            .141    0.728       0.362‐1.464     .373
  T3                   151   1.869                  0.931‐3.750                            .078    1.176       0.573‐2.415     .658
  T4                   145   1.306                  0.652‐2.613                            .451    0.910       0.444‐1.865     .797
  N                                                                                        .645                                .454
  N0                   40    Ref.                                                                  Ref.                        
  N1                   84    0.804                  0.343‐1.885                            .616    0.846       0.332‐2.157     .726
  N2                   305   0.966                  0.448‐2.082                            .929    0.643       0.277‐1.491     .303
  N3                   78    0.676                  0.275‐1.664                            .394    0.936       0.354‐2.476     .894
  M                          1.503                  0.789‐2.862                            .215    1.263       0.654‐2.439     .487
  M0                   436   Ref.                                                                  Ref.                        
  M1                   71                                                                                                      
  Histology                                                                                .389                                .699
  Keratinizing\*       12    Ref.                                                                  Ref.                        
  Non‐Keratinizing\#   479   0.913                  0.233‐3.585                            .897    1.398       0.394‐4.967     .604
  Unknown              16    2.192                  0.354‐13.578                           .399    0.948       0.181‐4.947     .949
  SIRI                       0.545                  0.294‐1.010                            .054    1.213       0.618‐2.383     .574
  \<1.529              367   Ref.                                                                  Ref.                        
  ≥1.529               140                                                                                                     
  NLR                        1.798                  0.904‐3.578                            .095    1.200       0.533‐2.705     .659
  \<3.441              377   Ref.                                                                  Ref.                        
  ≥3.441               130                                                                                                     
  SII                        0.785                  0.356‐1.730                            .548    0.862       0.385‐1.929     .718
  \<715.739            384   Ref.                                                                  Ref.                        
  ≥715.739             123                                                                                                     
  PLR                        1.341                  0.570‐3.158                            .501    3.379       1.696‐6.731     .001
  \<245.496            442   Ref.                                                                  Ref.                        
  ≥245.496             65                                                                                                      
  WBC                                                                                      .229                                .082
  Normal               341   Ref.                                                                  Ref.                        
  Low                  146   0.603                  0.286‐1.268                            .182    0.743       0.349‐1.584     .442
  High                 20    3.175                  0.468‐21.537                           .237    8.051       1.209‐53.639    .031
  RBC                                                                                      .201                                .282
  Normal               324   Ref.                                                                  Ref.                        
  Low                  178   1.597                  0.860‐2.964                            0.138   1.667       0.888‐3.126     .112
  High                 5     0.277                  0.027‐2.884                            0.283   1.026E+09   0‐              .999
  HGB                        0.537                  0.357‐0.809                            0.003   0.646       0.348‐1.198     .165
  Normal               330   Ref.                                                                  Ref.                        
  Low                  177                                                                                                     
  PLT                                                                                      .008                                .430
  Normal               455   Ref.                                                                  Ref.                        
  Low                  15    1.258                  0.411‐3.849                            .688    2.534       0.620‐10.355    .195
  High                 37    4.547                  1.743‐11.861                           .002    1.074       0.441‐2.618     .875
  NEU                                                                                      .080                                .067
  Normal               370   Ref.                                                                  Ref.                        
  Low                  109   0.680                  0.417‐1.110                            .123    1.594       0.746‐3.405     .229
  High                 28    0.456                  0.175‐1.185                            .107    0.179       0.034‐0.945     .043
  LYM                                                                                      .008                                .281
  Normal               379   Ref.                                                                  Ref.                        
  Low                  127   2.325                  1.365‐3.960                            .002    1.756       0.879‐3.508     .111
  High                 1     1.111E+08              0‐                                     .999    1.380E+09   0‐              .999
  MONO                       2.277                  1.053‐4.925                            .036    1.482       0.657‐3.341     .343
  Normal               463   Ref.                                                                  Ref.                        
  High                 44                                                                                                      
  EO                                                                                       .042                                .006
  Normal               210   Ref.                                                                  Ref.                        
  Low                  290   0.606                  0.406‐0.905                            .014    0.525       0.351‐0.784     .002
  High                 7     1.239                  0.222‐6.927                            .807    0.408       0.082‐2.027     .273
  BASO                       0.192                  0.044‐0.833                            .027    1.558       0.302‐8.027     .596
  Normal               497   Ref.                                                                  Ref.                        
  High                 10                                                                                                      
  HCT                        0.841                  0.502‐1.409                            .512    0.555       0.359‐0.856     .008
  Normal               154   Ref.                                                                  Ref.                        
  Low                  353                                                                                                     
  MCV                                                                                      .987                                .222
  Normal               483   Ref.                                                                  Ref.                        
  Low                  13    3.780E+09              0‐                                     .999    3.925E+09   0‐              .999
  High                 11    1.143                  0.233‐5.609                            .869    10.494      0.736‐149.530   .083
  MCH                                                                                      .417                                .490
  Normal               485   Ref.                                                                  Ref.                        
  Low                  12    0.000                  0‐                                     .999    0.000       0‐              .999
  High                 10    3.542                  0.544‐23.063                           .186    0.300       0.042‐2.160     .232
  MCHC                                                                                     .948                                .755
  Normal               481   Ref.                                                                  Ref.                        
  Low                  23    1.157                  0.367‐3.650                            .803    0.823       0.263‐2.580     .739
  High                 3     1.447                  0.046‐45.566                           .834    2.876       0.134‐61.970    .500
  RDW                        1.001                  0.528‐1.895                            .998    1.353       0.690‐2.654     .378
  Normal               436   Ref.                                                                  Ref.                        
  High                 71                                                                                                      
  MPV                        0.373                  0.014‐9.990                            .557    1.712E+08   0‐              .999
  Normal               505   Ref.                                                                  Ref.                        
  High                 2                                                                                                       
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###### 

Effects of clinical parameters and hemograms on the dysphagia and gastrointestinal reaction in NPC patients (n = 507)

  Variables            n     Dysphagia   Gastrointestinal reaction                                     
  -------------------- ----- ----------- --------------------------- ------ ----------- -------------- -------
  Sex                        1.095       0.663‐1.806                 .724   0.560       0.345‐0.909    .019
  Male                 386   Ref.                                           Ref.                       
  Female               121                                                                             
  Age                        1.216       0.721‐2.052                 .462   1.762       0.996‐3.117    .052
  \<60 years           389   Ref.                                           Ref.                       
  ≥60 years            118                                                                             
  T                                                                  .852                              .289
  T1                   62    Ref.                                           Ref.                       
  T2                   149   0.857       0.419‐1.751                 .672   1.108       0.503‐2.437    .800
  T3                   151   1.012       0.488‐2.102                 .974   1.144       0.509‐2.570    .745
  T4                   145   0.818       0.395‐1.694                 .588   0.685       0.310‐1.516    .351
  N                                                                  .198                              .103
  N0                   40    Ref.                                           Ref.                       
  N1                   84    0.968       0.374‐2.509                 .947   0.969       0.346‐2.713    .953
  N2                   305   0.590       0.252‐1.381                 .224   0.636       0.258‐1.565    .325
  N3                   78    0.917       0.343‐2.450                 .862   1.454       0.485‐4.359    .504
  M                          1.738       0.918‐3.288                 .089   4.129       1.738‐9.807    .001
  M0                   436   Ref.                                           Ref.                       
  M1                   71                                                                              
  Histology                                                          .663                              .859
  Keratinizing\*       12    Ref.                                           Ref.                       
  Non‐Keratinizing\#   479   0.908       0.231‐3.560                 .890   1.106       0.278‐4.404    .886
  Unknown              16    0.550       0.098‐3.089                 .497   0.807       0.139‐4.675    .811
  SIRI                       1.073       0.538‐2.136                 .842   2.115       1.137‐3.932    .018
  \<1.529              367   Ref.                                           Ref.                       
  ≥1.529               140                                                                             
  NLR                        1.150       0.500‐2.643                 .742   0.738       0.297‐1.833    .512
  \<3.441              377   Ref.                                           Ref.                       
  ≥3.441               130                                                                             
  SII                        1.321       0.579‐3.014                 .509   0.933       0.377‐2.308    .881
  \<715.739            384   Ref.                                           Ref.                       
  ≥715.739             123                                                                             
  PLR                        2.626       1.304‐5.289                 .007   1.825       0.690‐4.822    .225
  \<245.496            442   Ref.                                           Ref.                       
  ≥245.496             65                                                                              
  WBC                                                                .239                              .070
  Normal               341   Ref.                                           Ref.                       
  Low                  146   0.787       0.364‐1.704                 .544   1.521       0.739‐3.133    .255
  High                 20    4.568       0.730‐28.573                .104   6.415       1.039‐39.610   .045
  RBC                                                                .643                              .876
  Normal               324   Ref.                                           Ref.                       
  Low                  178   1.350       0.722‐2.525                 .347   0.837       0.425‐1.649    .607
  High                 5     1.095E+09   0‐                          .999   1.990E+08   0‐             .999
  HGB                        0.920       0.498‐1.699                 .790   0.922       0.476‐1.784    .810
  Normal               330   Ref.                                           Ref.                       
  Low                  177                                                                             
  PLT                                                                .345                              .834
  Normal               455   Ref.                                           Ref.                       
  Low                  15    2.132       0.508‐8.948                 .301   1.603       0.344‐7.472    .548
  High                 37    0.633       0.260‐1.545                 .316   0.991       0.364‐2.701    .986
  NEU                                                                .045                              .046
  Normal               370   Ref.                                           Ref.                       
  Low                  109   1.532       0.703‐3.339                 .284   1.009       0.466‐2.185    .981
  High                 28    0.148       0.029‐0.765                 .023   0.139       0.029‐0.659    .013
  LYM                                                                .340                              .967
  Normal               379   Ref.                                           Ref.                       
  Low                  127   1.699       0.838‐3.445                 .142   1.103       0.523‐2.328    .797
  High                 1     2.848E+09   0‐                          .999   0.000       0‐             .999
  MONO                       1.367       0.605‐3.091                 .452   0.494       0.223‐1.094    .082
  Normal               463   Ref.                                           Ref.                       
  High                 44                                                                              
  EO                                                                 .008                              0.002
  Normal               210   Ref.                                           Ref.                       
  Low                  290   0.536       0.357‐0.806                 .003   0.440       0.275‐0.702    .001
  High                 7     0.334       0.068‐1.640                 .177   0.968       0.094‐9.979    .978
  BASO                       3.606       0.416‐31.228                .244   0.429       0.094‐1.964    .275
  Normal               497   Ref.                                           Ref.                       
  High                 10                                                                              
  HCT                        0.477       0.303‐0.749                 .001   0.526       0.320‐0.866    .012
  Normal               154   Ref.                                           Ref.                       
  Low                  353                                                                             
  MCV                                                                .380                              .722
  Normal               483   Ref.                                           Ref.                       
  Low                  13    3.791E+09   0‐                          .999   8.486E+08   0‐             .998
  High                 11    5.437       0.500‐59.136                .164   2.376       0.290‐19.440   .420
  MCH                                                                .959                              .984
  Normal               485   Ref.                                           Ref.                       
  Low                  12    0.000       0‐                          .999   0.000       0‐             .999
  High                 10    0.766       0.127‐4.609                 .771   0.843       0.129‐5.526    .859
  MCHC                                                               .831                              .525
  Normal               481   Ref.                                           Ref.                       
  Low                  23    1.310       0.401‐4.284                 .655   0.880       0.223‐3.477    .855
  High                 3     1.889       0.089‐40.170                .684   0.128       0.003‐4.683    .263
  RDW                        1.713       0.935‐3.139                 .082   1.156       0.551‐2.426    .701
  Normal               436   Ref.                                           Ref.                       
  High                 71                                                                              
  MPV                        0.104       0.004‐2.806                 .178   2.031E+08   0‐             .999
  Normal               505   Ref.                                           Ref.                       
  High                 2                                                                               
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###### 

Effects of clinical parameters and hemograms on the innutrition in NPC patients (n = 507)

  Variables            n     Innutrition                  
  -------------------- ----- ------------- -------------- ------
  Sex                        1.397         0.808‐2.417    .232
  Male                 386   Ref.                         
  Female               121                                
  Age                        0.589         0.364‐0.952    .031
  \<60                 389   Ref.                         
  ≥60                  118                                
  T                                                       .522
  T1                   62    Ref.                         
  T2                   149   1.597         0.756‐3.372    .220
  T3                   151   1.221         0.581‐2.566    .599
  T4                   145   1.092         0.517‐2.305    .818
  N                                                       .863
  N0                   40    Ref.                         
  N1                   84    0.704         0.279‐1.776    .457
  N2                   305   0.877         0.377‐2.037    .760
  N3                   78    0.867         0.326‐2.311    .776
  M                          0.723         0.380‐1.375    .323
  M0                   436   Ref.                         
  M1                   71                                 
  Histology                                               .832
  Keratinizing\*       12    Ref.                         
  Non‐Keratinizing\#   479   0.592         0.108‐3.228    .544
  Unknown              16    0.607         0.077‐4.775    .635
  SIRI                       0.869         0.419‐1.803    .707
  \<1.529              367   Ref.                         
  ≥1.529               140                                
  NLR                        1.744         1.044‐2.915    .034
  \<3.441              377   Ref.                         
  ≥3.441               130                                
  SII                        1.140         0.482‐2.697    .765
  \<715.739            384   Ref.                         
  ≥715.739             123                                
  PLR                        0.887         0.365‐2.156    .792
  \<245.496            442   Ref.                         
  ≥245.496             65                                 
  WBC                                                     .913
  Normal               341   Ref.                         
  Low                  146   0.918         0.402‐2.097    .840
  High                 20    1.508         0.195‐11.680   .694
  RBC                                                     .084
  Normal               324   Ref.                         
  Low                  178   1.728         0.933‐3.198    .082
  High                 5     0.134         0.009‐2.060    .149
  HGB                        0.400         0.219‐0.731    .003
  Normal               330   Ref.                         
  Low                  177                                
  PLT                                                     .284
  Normal               455   Ref.                         
  Low                  15    5.506         0.668‐45.413   .113
  High                 37    0.982         0.393‐2.449    .968
  NEU                                                     .551
  Normal               370   Ref.                         
  Low                  109   0.886         0.391‐2.006    .771
  High                 28    0.380         0.061‐2.362    .300
  LYM                                                     .700
  Normal               379   Ref.                         
  Low                  127   1.380         0.653‐2.918    .399
  High                 1     2.877E+08     0‐             .999
  MONO                       1.994         0.797‐4.986    .140
  Normal               463   Ref.                         
  High                 44                                 
  EO                                                      .874
  Normal               210   Ref.                         
  Low                  290   0.948         0.595‐1.510    .822
  High                 7     0.631         0.101‐3.944    .622
  BASO                       0.288         0.081‐1.029    .055
  Normal               497   Ref.                         
  High                 10                                 
  HCT                        0.798         0.449‐1.420    .443
  Normal               154   Ref.                         
  Low                  353                                
  MCV                                                     .089
  Normal               483   Ref.                         
  Low                  13    6.745         0.782‐58.147   .082
  High                 11    4.279         0.527‐34.729   .174
  MCH                                                     .900
  Normal               485   Ref.                         
  Low                  12    0.000         0‐             .999
  High                 10    0.627         0.085‐4.619    .647
  MCHC                                                    .998
  Normal               481   Ref.                         
  Low                  23    0.963         0.298‐3.113    .949
  High                 3     9.231E+08     0‐             .999
  RDW                        1.118         0.560‐2.235    .752
  Normal               436   Ref.                         
  High                 71                                 
  MPV                        9.915E+07     0‐             .999
  Normal               505   Ref.                         
  High                 2                                  

John Wiley & Sons, Ltd

3.4. Clinical characteristics of immune‐inflammation indicators in survival analysis {#jcmm15097-sec-0012}
------------------------------------------------------------------------------------

Finally, a total of 255 patients were enrolled in the study for survival analysis. A total of 202 male and 53 female patients in 255 patients with NPC were included (Table [1](#jcmm15097-tbl-0001){ref-type="table"}). Patients' median age was 51 years (range 12‐78 years). The association between clinical characteristics and immune‐inflammation indicators, such as SIRI, SII, NLR, neutrophil, monocyte and WBC, was shown in Table [7](#jcmm15097-tbl-0007){ref-type="table"}. Among clinical groups of N stage and histology, there were no significant differences in inflammation indicators. We also examined the association between these immune‐inflammation indicators and other haematological indexes. The results showed that there were associations between these indicators and other haematological indicators, including SIRI, NLR, SII, neutrophil, monocyte, WBC and platelet, while most indicators had no difference in RDW. Inflammation indicators also had a significant difference between low and high group of basophils except NLR. Moreover, there was a significant difference between PLR and combined immune indicators such as SIRI, NLR and SII, while no difference in neutrophil, monocyte and WBC.

###### 

Baseline characteristics for patients with SIRI, NLR, SII, Neutrophil, Monocyte and WBC (n = 255)

  Variables            SIRI   NLR    SII    Neutrophil   Monocyte   WBC
  -------------------- ------ ------ ------ ------------ ---------- ------
  Therapy              .759   .208   .277   .120         .603       .126
  Untreated                                                         
  Chemotherapy                                                      
  Radiotherapy                                                      
  Sex                  .029   .501   .695   .003         .175       .029
  Female                                                            
  Male                                                              
  Age                  .010   .093   .054   .064         .120       .433
  \<60                                                              
  ≥60                                                               
  T                    .262   .129   .042   .711         .941       .656
  T1                                                                
  T2                                                                
  T3                                                                
  T4                                                                
  N                    .323   .557   .819   .886         .633       .490
  N0                                                                
  N1                                                                
  N2                                                                
  N3                                                                
  M                    .006   .080   .043   .212         .034       .972
  M0                                                                
  M1                                                                
  Histology            .681   .440   .317   .155         .316       .799
  Keratinizing\*                                                    
  Non‐Keratinizing\#                                                
  Unknown                                                           
  SIRI                        .000   .000   .000         .000       .000
  \<1.529                                                           
  ≥1.529                                                            
  NLR                  .000          .000   .000         .053       .000
  \<3.441                                                           
  ≥3.441                                                            
  SII                  .000   .000          .000         .063       .000
  \<715.739                                                         
  ≥715.739                                                          
  NEU                  .000   .000   .000                .000       .000
  \<2.722                                                           
  ≥2.722                                                            
  MONO                 .000   .053   .063   .000                    .000
  \<0.578                                                           
  ≥0.578                                                            
  WBC                  .000   .000   .000   .000         .000       
  \<6.177                                                           
  ≥6.177                                                            
  PLT                  .004   .036   .000   .000         .000       .000
  \<267.583                                                         
  ≥267.583                                                          
  BASO                 .006   .402   .012   .000         .000       .001
  \<0.029                                                           
  ≥0.029                                                            
  PLR                  .000   .000   .000   .354         .243       .967
  \<245.496                                                         
  ≥245.496                                                          
  RDW                  .028   .146   .135   .810         .737       .166
  \<14.495                                                          
  ≥14.495                                                           
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3.5. Associations of immune‐inflammation indicators with survival {#jcmm15097-sec-0013}
-----------------------------------------------------------------

The study took OS and DFS as the primary and secondary outcome, respectively. The median follow‐up time was 33.5 months (range 2.1‐151.2) for OS and 28.4 months (range 1‐151.2) for DFS. Based on the cut‐off values by ROC curve, patients were subdivided into low‐score and high‐score groups of various indicators. Compared with lower scores of haematological indicators, higher scores were associated with significantly worse OS in NPC patients, while it had little effect on DFS except for PLR (Figure [7](#jcmm15097-fig-0007){ref-type="fig"}). By Kaplan‐Meier analysis and the log‐rank test, high‐score SIRI, NLR, SII, neutrophil, monocyte, WBC, platelet, basophil, PLR and RDW were associated with poor OS, while only high‐score PLR was associated with poor DFS (Figure [7](#jcmm15097-fig-0007){ref-type="fig"}). In univariate Cox regression analysis, OS was significantly affected by age, M stage, SIRI, NLR, SII, neutrophil, monocyte, WBC, platelet, basophil, PLR and RDW (Table [8](#jcmm15097-tbl-0008){ref-type="table"}), and DFS was affected by M stage and PLR (Table [9](#jcmm15097-tbl-0009){ref-type="table"}), while the histopathological classification had no effect on OS or DFS. In multivariate Cox regression analysis, for OS, age (*P* = 0.002; HR = 5.061; 95%CI: 1.832‐13.983), M stage (*P* = 0.023; HR = 3.848; 95% CI: 1.204‐12.302), PLR (*P* = 0.035; HR = 3.480; 95%CI: 1.090‐11.117), WBC (*P* = 0.006; HR = 3.500; 95%CI: 1.422‐8.617) and RDW (*P* = 0.008; HR = 3.489; 95%CI: 1.380‐8.818) were independent prognostic risk factors (Table [8](#jcmm15097-tbl-0008){ref-type="table"}). And for DFS, M stage (*P* = .003; HR = 2.862; 95%CI: 1.419‐5.773) and PLR (*P* = 0.017; HR = 2.250; 95%CI: 1.153‐4.394) were independent prognostic risk factors (Table [9](#jcmm15097-tbl-0009){ref-type="table"}).

![Inflammation indicators predict survival in NPC. Estimated overall survival (OS) (A) and disease‐free survival (DFS) (B) curves for SIRI, NLR, SII and PLR. OS (C) and DFS (D) curves for MONO, WBC, BASO, PLT and RDW. Radiotherapy included radiotherapy alone or chemoradiotherapy](JCMM-24-8326-g007){#jcmm15097-fig-0007}

###### 

Univariate and multivariate Cox proportional hazards regression analysis for OS

  Variables            Univariate   Multivariate                                 
  -------------------- ------------ -------------- ------ ------- -------------- ------
  Therapy                                          .054                          
  Untreated            Ref.                                                      
  Chemotherapy         0.277        0.017‐4.515    .367                          
  Radiotherapy         0.086        0.010‐0.718    .023                          
  Sex                  1.218        0.478‐3.103    .679                          
  Female               Ref.                                                      
  Male                                                                           
  Age                  3.091        1.359‐7.033    .007   5.061   1.832‐13.983   .002
  \<60                 Ref.                               Ref.                   
  ≥60                                                                            
  T                                                .089                          
  T1                   Ref.                                                      
  T2                   1.087        0.113‐10.492   .942                          
  T3                   1.639        0.191‐14.069   .652                          
  T4                   3.920        0.512‐29.990   .188                          
  N                                                .395                          
  N0                   Ref.                                                      
  N1                   1.681        0.174‐16.210   .653                          
  N2                   1.108        0.144‐8.548    .922                          
  N3                   2.453        0.300‐20.074   .403                          
  M                    4.345        1.837‐10.279   .001   3.848   1.204‐12.302   .023
  M0                   Ref.                               Ref.                   
  M1                                                                             
  Histology                                        .983                          
  Keratinizing\*       Ref.                                                      
  Non‐Keratinizing\#   6.277E+04    0‐2.123E+275   .972                          
  Unknown              7.574E+04    0‐2.570E+275   .972                          
  SIRI                 4.355        1.789‐10.600   .001   0.785   0.145‐4.250    .779
  \<1.529              Ref.                               Ref.                   
  ≥1.529                                                                         
  NLR                  4.005        1.633‐9.820    .002   2.354   0.507‐10.935   .275
  \<3.441              Ref.                               Ref.                   
  ≥3.441                                                                         
  SII                  3.717        1.595‐8.658    .002   0.571   0.085‐3.858    .566
  \<715.739            Ref.                               Ref.                   
  ≥715.739                                                                       
  NEU                  5.170        1.210‐22.094   .027   5.821   0.881‐38.448   .067
  \<2.722              Ref.                               Ref.                   
  ≥2.722                                                                         
  MONO                 4.464        1.961‐10.158   .000   1.238   0.338‐4.532    .747
  \<0.578              Ref.                               Ref.                   
  ≥0.578                                                                         
  WBC                  3.864        1.697‐8.801    .001   3.500   1.422‐8.617    .006
  \<6.177              Ref.                               Ref.                   
  ≥6.177                                                                         
  PLT                  4.448        1.881‐10.519   .001   1.354   0.385‐4.760    .637
  \<267.583            Ref.                               Ref.                   
  ≥267.583                                                                       
  BASO                 4.060        1.599‐10.309   .003   1.533   0.511‐4.597    .446
  \<0.029              Ref.                               Ref.                   
  ≥0.029                                                                         
  PLR                  4.123        1.767‐9.617    .001   3.480   1.090‐11.117   .035
  \<245.496            Ref.                               Ref.                   
  ≥245.496                                                                       
  RDW                  2.946        1.290‐6.729    .010   3.489   1.380‐8.818    .008
  \<14.495             Ref.                               Ref.                   
  ≥14.495                                                                        
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###### 

Univariate and multivariate Cox proportional hazards regression analysis for DFS

  Variables            Univariate   Multivariate                                  
  -------------------- ------------ ---------------- ------ ------- ------------- ------
  Therapy                                            .757                         
  Untreated            Ref.                                                       
  Chemotherapy         1.008        0.000‐4.37E+07   .999                         
  Radiotherapy         21.961       0.000‐5.20E+07   .680                         
  Sex                  1.345        0.694‐2.604      .380                         
  Female               Ref.                                                       
  Male                                                                            
  Age                  1.080        0.548‐2.130      .824                         
  \<60                 Ref.                                                       
  ≥60                                                                             
  T                                                  .247                         
  T1                   Ref.                                                       
  T2                   0.810        0.214‐3.064      .756                         
  T3                   1.442        0.412‐5.043      .567                         
  T4                   1.837        0.541‐6.238      .330                         
  N                                                  .664                         
  N0                   Ref.                                                       
  N1                   0.704        0.157‐3.148      .646                         
  N2                   0.895        0.271‐2.960      .856                         
  N3                   1.329        0.363‐4.872      .668                         
  M                    3.672        1.886‐7.149      .000   2.862   1.419‐5.773   .003
  M0                   Ref.                                 Ref.                  
  M1                                                                              
  Histology                                          .771                         
  Keratinizing\*       Ref.                                                       
  Non‐Keratinizing\#   2.318E+04    0‐5.518E+110     .936                         
  Unknown              3.620E+04    0‐1.516E‐102     .933                         
  PLR                  2.948        1.557‐5.581      .001   2.250   1.153‐4.394   .017
  \<245.496            Ref.                                 Ref.                  
  ≥245.496                                                                        
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4. DISCUSSION {#jcmm15097-sec-0014}
=============

In the current study, we found that SIRI, SII, NLR, PLR, neutrophil, monocyte and RDW score were valuable for the prediction of both diagnosis and prognosis of NPC.

Compared with patients with a low score, patients who had a high SIRI score had a shorter OS, as well as SII, NLR, PLR, neutrophil, monocyte, RDW and basophil. Chen et al[20](#jcmm15097-bib-0020){ref-type="ref"} also reported the efficacy of SIRI in evaluating the prognosis of NPC, which was consistent with our study. In the univariate Cox regression analysis of our research, inflammation indicators, including SIRI, SII, NLR, PLR, neutrophil, monocyte, RDW and basophils, had a significant correlation with OS, while PLR, WBC, RDW, M stage and age were independent prognostic factors in multivariate Cox regression analysis. The risks of death in patients who attributed to the high‐score groups of the PLR, WBC, RDW, M stage and age were 3.48, 3.5, 3.489, 3.848 and 5.061 times higher than those in the low‐score group of the PLR, WBC, RDW, M stage and age, respectively. Besides, M stage and PLR were also the independent prognostic risk factors for DFS, and the risks of death in the high‐score group of the M stage and PLR were 2.862 and 2.25 times higher than those in the low‐score group of them.

Chronic inflammation plays a vital role in the initiation and development of cancer, which makes individuals susceptible to various types of cancer.[21](#jcmm15097-bib-0021){ref-type="ref"} Inflammation was associated with cancer,[22](#jcmm15097-bib-0022){ref-type="ref"} such as inflammatory bowel disease with colon cancer, helicobacter pylori infection with gastric cancer and prostatitis with prostate cancer. It has also been reported that patients with chronic rhinosinusitis (CRS) or allergic rhinitis (AR) have increased risk of NPC.[23](#jcmm15097-bib-0023){ref-type="ref"} In our study, we compared inflammation indicators of NPC patients with chronic rhinitis patients; then, we conducted a prognostic analysis of haematological indicators for diagnosis of NPC. We found a significant difference between the NPC and rhinitis for immune‐inflammation indicators, such as SIRI, NLR, SII, PLR, neutrophil and monocytes. And PLR was the best predictor of diagnosis of NPC.

Cancers can convert the peripheral matrix to promote progression. The changes involve recruitment of fibroblasts, migration of immune cells and formation of vascular networks. Tumour microenvironment (TME) comprises various cells and extracellular components. Excessive proliferation of cancer cells can stimulate the production of cytokines and chemokines, which attract immune cells to the TME and induce local immune inflammation.[21](#jcmm15097-bib-0021){ref-type="ref"} Diem et al reported that NLR and PLR in the tumour microenvironment were associated with prognosis of lung cancer.[24](#jcmm15097-bib-0024){ref-type="ref"} In addition, the circulating monocytes that play a major role in innate immunity may reflect the level of tumour‐associated macrophages (TAMs), while TAMs can directly stimulate the growth, migration and metastasis of cancer cells.[25](#jcmm15097-bib-0025){ref-type="ref"} Also, the platelet can promote tumour growth and metastasis owing to affecting cancer cells and other cells in the TME.[26](#jcmm15097-bib-0026){ref-type="ref"} The different cell types in the TME communicate with each other to support cancer development; for example, SIRI and SII, the combination of NLR and monocyte and platelet, were associated with the prognosis of cancer patients.[19](#jcmm15097-bib-0019){ref-type="ref"}, [27](#jcmm15097-bib-0027){ref-type="ref"} Neutrophils can promote angiogenesis by pro‐inflammatory cytokines, matrix metalloprotease 9 (MMP9) and VEGF, and can promote tumoral motility, migration and invasion.[28](#jcmm15097-bib-0028){ref-type="ref"} Contrary to the pro‐tumour function of neutrophils, monocytes and platelets in malignant carcinomas, lymphocytes play an important role in antitumor immune response.[29](#jcmm15097-bib-0029){ref-type="ref"}

Most researches have suggested that the neutrophil, monocyte and platelet are pro‐tumour indicators, while lymphocyte regarded as an antitumour indicator. We combine the two or three immunology indicators as prognostic factors, such as SIRI, SII, NLR and PLR, which can enhance the predictive value of the diagnosis and prognosis of tumours. The combined inflammation indicators, low cost and reliable, can be used to supply the current evaluation system of TNM staging system to help evaluate the individualized therapy and prognosis of these patients.

Moreover, RDW is also a potential marker in tumour progression. Mechanically, iron metabolism in red blood cells is affected by inflammatory factors, which induces the release of lots of immature red blood cells from the bone marrow in advance, and inflammatory factors also increase ineffective haematopoiesis in the bone marrow, which together induced a change in the RDW.[30](#jcmm15097-bib-0030){ref-type="ref"} Wang et al reported that RDW and body mass index (COR‐BMI) might serve as an inflammation‐ and nutrition‐based indicator of prognosis in NPC.[31](#jcmm15097-bib-0031){ref-type="ref"} Consistently, our results showed that RDW might help to predict the diagnosis and prognosis of NPC. The association between basophil and NPC has not been reported so far. In our study, NPC patients with high‐score basophils had poor OS, which testified that basophil might participate in predicting the prognosis of NPC.

Besides, the NPC incidence of males is higher than that of females, and 50‐ to 60‐year‐olds are typical peaks. The ageing of the immune system may result in detrimental consequences on the response against cancers; then, the inflammatory status can promote immune suppression and cancer growth.[32](#jcmm15097-bib-0032){ref-type="ref"} In our study, the incidence of NPC in males was three times higher than in females, and the incidence of patients who were under 60 years was three times higher than in those older than 60 years. And the risks of death of patients in the period of older than 60 years were 5.061 times higher than those in lower age.

Radiotherapy can affect the health‐related quality of life (QOL) in patients with NPC, such as dysphagia.[33](#jcmm15097-bib-0033){ref-type="ref"} To guarantee the QOL of NPC patients, we investigated the influencing factors for side effects of treatment. We have analysed the influence of clinical parameters and haemograms on side effects in NPC patients based on the reference range of haemogram. The therapies induced most side effects, such as the arrest of bone marrow, radiation stomatitis and dermatitis. Sex, age and M stage have effects on these side effects. Besides, we find that inflammation indicators have significance on various side effects, including the NLR, monocyte, lymphocyte, platelet, eosinophil, basophils, PLR and SIRI.

The summary of the inadequacy of our study is as follows. Most patients with NPC fail to follow‐up, and patients almost diagnosed with non‐keratinizing carcinoma, only 2.4% NPC patients diagnosed with keratinizing squamous cell carcinoma, which may explain why most immunological indicators were not statistically significant in histopathological groups and histology had no effect on side effects and survival in our study. Besides, the items of EB virus load and correlated antibody were regarded as regular tests for patients with NPC in August 2017 in our hospital, while this retrospective study performed in 2014. The correlation between immunological indicators and EBV is not analysed.

In conclusion, the inflammation indicators, such as SIRI, SII, NLR, PLR, neutrophil, monocyte and RDW, can be used to predict the diagnosis and prognosis of NPC. Furthermore, many indicators are closely related to side effects and survival. Because the biological diversity of the tumour has not been taken into account, the current TNM staging system that most common parameters used in therapeutic decision and assessing the curative effect in patients with NPC leads to heterogeneous curative effects in patients with identical TNM staging. The inflammation indicators can replenish the current TNM staging system to help evaluate treatment decision and prognosis. It deserves us to focus on these blood indicators associated with tumour‐related inflammation.
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